SAFETYLIT WEEKLY UPDATE

We compile citations and summaries of about 400 new articles every week.
RSS Feed

HELP: Tutorials | FAQ
CONTACT US: Contact info

Search Results

Journal Article

Citation

Osuch E, Marais A. SA Pharmaceutical Journal 2021; 88(6): 26-35.

Copyright

(Copyright © 2021)

DOI

unavailable

PMID

unavailable

Abstract

Depression affects nearly 350 million people worldwide. Local data indicates that approximately 17% of all South Africans will experience at least one episode of depression in their lifetime. Depressive disorders contribute significantly towards overall morbidity and increased risk for suicide. Antidepressant therapy remains one of the cornerstones in the management of depressive disorders. Although the efficacy of antidepressive drugs is continuously subjected to criticism, thousands of controlled clinical trials have shown, and will continue to show, their benefit in the effective treatment of depressive disorders. Since the introduction of antidepressants in the early 1950s, researchers have been searching for an ideal antidepressant able to adequately reduce, preserve and prevent features of depression with the absence of side effects. This article summarises the currently available antidepressant drugs in South Africa. Discontinued products have been omitted and newly registered agents have been added. This review does not contain reference to any experimental drug, or substances not yet available for local use. © 2021 Medpharm Publications. All rights reserved.


Language: en

Keywords

human; Review; South Africa; herbal medicine; depression; major depressive disorder; treatment outcome; antidepressant; pregnancy; serotonin; antidepressant agent; child psychiatry; clinical feature; monoamine oxidase inhibitor; noradrenalin uptake inhibitor; pathophysiology; serotonin antagonist; serotonin uptake inhibitor; tricyclic antidepressant agent; unclassified drug; dopamine; dopamine uptake inhibitor; psychopharmacotherapy; geriatric patient; breast feeding; gerontopsychiatry; herbaceous agent; serotonin noradrenalin reuptake inhibitor; postnatal depression; tetracyclic antidepressant agent; treatment resistant depression; pediatric patient; antenatal depression; melatonergic agonist; noradrenaline

NEW SEARCH


All SafetyLit records are available for automatic download to Zotero & Mendeley
Print